# Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and Nintedanib

> **NCT06717100** · PHASE1 · COMPLETED · sponsor: **PureTech** · enrollment: 24 (actual)

## Conditions studied

- Drug Interactions

## Interventions

- **DRUG:** Nintedanib 150 MG [Ofev]

## Key facts

- **NCT ID:** NCT06717100
- **Lead sponsor:** PureTech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-12-17
- **Primary completion:** 2025-02-17
- **Final completion:** 2025-03-17
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2026-01-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06717100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06717100, "Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and Nintedanib". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06717100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*